Tailored weight-loss advice and prescription assessment

Our online service assesses adults seeking support with weight management. For many medicines, the adult weight-management licence covers a starting BMI of at least 30, or at least 27 with a weight-related condition such as high blood pressure. Criteria differ by medicine and NHS access rules are separate.

BMI alone does not determine suitability. Your prescriber considers your health, medicines, goals and any need for another service. Treatment may be unsuitable even if you meet a BMI threshold.

Your plan may focus on dietary and lifestyle changes, further assessment or referral. Where appropriate, your prescriber can discuss licensed medical treatments, their expected benefits, risks and alternatives. No particular medicine is guaranteed.

UK-licensed weight-management medicines include injectable and oral products. Authorisation does not establish current pharmacy stock or availability through MyPharmacyServices. We confirm suitability, our prescribing scope and pharmacy supply before any treatment is arranged. Unlicensed or unavailable products are not offered as routine treatment options.

Wegovy contains semaglutide, a GLP-1 receptor agonist that acts on appetite regulation. The injection is used alongside a reduced-calorie diet and increased activity for weight management in eligible patients. It is usually given once weekly, with gradual dose increases directed by the prescriber.

Benefits vary and treatment requires review. Common adverse effects include nausea, vomiting, diarrhoea, constipation and abdominal pain. Important risks include dehydration, gallbladder problems and pancreatitis. Tell your prescriber about diabetes, eye disease, kidney problems, stomach-emptying problems and all other medicines. Do not use if allergic to its ingredients.

Read the UK Wegovy injection patient leaflet, including the full warnings and instructions. Injection and tablet doses are not interchangeable.

Yes. The MHRA authorised Wegovy (semaglutide) tablets for adult weight management on 11 June 2026. This is a prescription-only, once-daily oral formulation, used with dietary changes and increased activity. It is distinct from the injection and from other semaglutide brands.

The tablet has specific fasting, water and waiting-time instructions that affect absorption. Follow the leaflet and prescription exactly; do not switch formulations or doses yourself. Nausea, vomiting, diarrhoea and constipation can occur, and the medicine carries important GLP-1 precautions. Suitability and ongoing benefit require review.

UK authorisation is confirmed; supply through this service and your pharmacy must be checked individually. Read the MHRA approval notice and UK Wegovy tablets patient leaflet.

Mounjaro contains tirzepatide, which acts at GIP and GLP-1 receptors. Its UK adult weight-management indication is alongside a reduced-calorie diet and increased activity in eligible patients. It is administered once weekly; the prescriber starts at a low dose and adjusts it gradually.

Common adverse effects include nausea, diarrhoea, vomiting and constipation. Risks include dehydration, pancreatitis, gallbladder problems and low blood sugar when combined with certain diabetes medicines. Discuss previous pancreatitis, severe digestive problems, eye disease and other medicines. Do not use if allergic to its ingredients. Results and tolerability vary.

Mounjaro can reduce oral contraceptive effectiveness: use an additional barrier method or switch to a non-oral method for four weeks after starting and for four weeks after each dose increase. Discuss pregnancy planning and contraception before treatment.

Read the UK Mounjaro KwikPen patient leaflet for the full safety information and device instructions.

Foundayo is the brand name for orforglipron. UK product information published in August 2026 confirms a prescription-only, once-daily film-coated tablet licensed for adult weight management alongside a reduced-calorie diet and increased activity. It also has a separate type 2 diabetes indication. It is not oral Mounjaro or oral Wegovy.

It acts at GLP-1 receptors and may support weight reduction, but benefit and tolerability differ between individuals. Common adverse effects include nausea, diarrhoea and vomiting. Important precautions include pancreatitis, dehydration, digestive problems and interactions with other medicines. Do not take it if allergic to its ingredients. Pregnancy, breastfeeding and contraception require discussion with your prescriber.

Licensing does not guarantee availability through this service or stock at your pharmacy. This section is information, not an offer of supply. Read the UK Foundayo patient leaflet for full indications, warnings and instructions.

Tell your prescriber if you are pregnant, trying for a baby or breastfeeding; have an eating disorder, previous pancreatitis, severe stomach or bowel problems, kidney or liver problems, diabetes complications, or recent bariatric surgery. These need individual assessment and may mean a different approach or referral is safer.

Do not combine weight-management medicines, use someone else’s prescription or change doses without advice. Tell any team planning surgery or sedation about these medicines, because they can affect stomach emptying. Each product has its own contraindications and warnings; read its UK leaflet.

Seek urgent medical advice for severe, persistent abdominal pain, which may spread to your back, with or without vomiting: this can be pancreatitis. Stop the medicine and obtain urgent assessment if pancreatitis is suspected. Persistent vomiting or diarrhoea can cause dehydration and also needs advice.

Call 999 for signs of a severe allergic reaction, such as breathing difficulty or swelling of the face or throat. Seek urgent advice for sudden loss of vision or a rapid change in eyesight. Report suspected side effects through the MHRA Yellow Card scheme; this does not replace medical care.

We usually begin with a one-month prescription where appropriate and review monthly. Reviews consider your progress, nutrition, side effects and whether continuing treatment is suitable. Dose changes and stopping decisions depend on the medicine and your clinical response.

If prescribed, an electronic private prescription can be sent to your chosen UK pharmacy. If you prefer home delivery, we can help arrange this through an online pharmacy, subject to prescription acceptance, stock and delivery arrangements. The dispensing pharmacy confirms the medicine price and any delivery charge, which are separate from our consultation fee. MyPharmacyServices provides consultations and prescribing; medicines are dispensed separately. Ask us about follow-up fees before arranging further appointments.

Yes. Dietary and lifestyle advice is part of the consultation whether or not medicine is appropriate. Your prescriber may recommend further checks or another service. You can discuss your concerns, preferences and alternatives before agreeing a plan.

Learn about your pharmacist prescriber, explore other pharmacist consultations or read our general consultation FAQs.